Every 8-K that Korro Bio, Inc. (KRRO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow KRRO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KRRO filings page.
Korro Bio, Inc. (KRRO) reports that on August 19, 2026 it submitted materials to the Australian Alfred Health Human Ethics Committee to initiate a first-in-human Phase 1/2 clinical trial for KRRO-121. KRRO-121 is a GalNAc-conjugated RNA editing oligonucleotide being developed for the potential treatment of hyperammonemia in patients with Urea Cycle Disorders.
The planned Phase 1/2 study is designed to evaluate safety and tolerability of escalating doses, characterize pharmacokinetics, and assess effects in both healthy volunteers and participants with Urea Cycle Disorders. Additional trial details are available at ClinicalTrials.gov under identifier NCT 07773246.
Korro Bio, Inc. entered into an exchange agreement with entities affiliated with Venrock Healthcare Capital Partners. Venrock will surrender 1,000,000 common shares to Korro for no consideration, and Korro will issue pre-funded warrants for 1,000,000 common shares with a $0.001 exercise price and no expiration. The warrants are immediately exercisable but include a 9.99% beneficial ownership cap. After the exchange, Korro will have 13,725,646 common shares outstanding and pre-funded warrants for 4,148,836 shares.
For the quarter ended June 30, 2026, Korro reported cash, cash equivalents and marketable securities of $137.9 million, supporting a projected cash runway into the second half of 2028. Research and development expenses were $13.6 million and general and administrative expenses were $6.5 million, contributing to a net loss of $18.9 million compared with $25.8 million a year earlier. Collaboration revenue was $0 versus $1.5 million in the prior-year quarter following a 12‑month pause of the Novo Nordisk collaboration.
Korro Bio, Inc. reported the results of its 2026 annual stockholder meeting held on June 10, 2026. Stockholders elected Nessan Bermingham and Rachel Meyers as Class I directors for three-year terms ending at the 2029 annual meeting.
Both directors received several million votes in favor, with additional votes withheld and broker non-votes recorded. Stockholders also approved, in a non-binding advisory vote, the compensation of Korro’s named executive officers by a wide margin.
In addition, stockholders ratified the selection of Ernst & Young LLP as Korro’s independent registered public accounting firm for the fiscal year ending December 31, 2026. These items collectively confirm continued support for the company’s board, executive pay program, and auditor.
Korro Bio reported a new development candidate, KRRO-111, added to its pipeline for the potential treatment of Alpha-1 Antitrypsin Deficiency (AATD). Preclinical mouse data showed more than 90% editing of the SERPINA1 transcript and about 90% repaired functional AAT protein in plasma.
KRRO-111, a subcutaneously delivered GalNAc‑conjugated oligonucleotide, nearly eliminated active Z‑protein production and drove progressive clearance of pre‑existing liver aggregates in PiZZ mouse models. Korro also reaffirmed its OPERA RNA editing platform strategy and noted $157.1 million in cash, cash equivalents and marketable securities as of March 31, 2026, which it expects to support operations into the second half of 2028.
Korro Bio reported first quarter 2026 results and highlighted progress across its RNA editing pipeline. Cash, cash equivalents and marketable securities were $157.1 million as of March 31, 2026, up from $85.2 million at year-end, helped by an oversubscribed $85 million private placement that is expected to fund operations into the second half of 2028.
The company advanced lead candidate KRRO-121 toward a planned regulatory filing in the second half of 2026 and achieved greater than 90% in vivo RNA editing in its GalNAc-conjugated AATD program. R&D expenses fell to $12.9 million from $19.7 million, while net loss narrowed to $19.6 million from $23.4 million year over year.
Korro Bio reported full-year 2025 results showing progress in its RNA-editing pipeline alongside higher losses. Collaboration revenue rose to $6.4 million from $2.3 million in 2024, while research and development expenses grew slightly to $65.6 million and general and administrative costs declined to $28.2 million.
The company recorded $30.9 million of non-cash long-lived asset impairment charges and $3.6 million in restructuring charges tied to 2025 workforce reductions, driving net loss to $117.3 million versus $83.6 million in 2024. Cash, cash equivalents and marketable securities were $85.2 million as of December 31, 2025, and an oversubscribed $85 million private placement completed in March 2026 is expected to fund operations into the second half of 2028.
Operationally, Korro nominated KRRO-121 as a development candidate for hyperammonemia in urea cycle disorders and hepatic encephalopathy, advanced its GalNAc-conjugated alpha-1 antitrypsin deficiency program with plans to nominate a candidate in the second quarter of 2026, and continued preclinical work in longevity, liver health, and ALS.
Korro Bio, Inc. entered into a subscription agreement for an oversubscribed private placement expected to deliver approximately $85.0 million in gross proceeds. The company will sell 4,501,928 shares of common stock at $11.11 per share and pre-funded warrants to purchase 3,148,836 shares at $11.109 per warrant, with a $0.001 exercise price.
The financing, led by Venrock Healthcare Capital Partners with multiple new and existing institutional investors, together with Korro’s preliminary unaudited $85.2 million in cash, cash equivalents and marketable securities as of December 31, 2025, is expected to extend the company’s cash runway into the second half of 2028. Proceeds are intended to advance Korro’s RNA editing pipeline, including clinical data for KRRO-121 in urea cycle disorders, its GalNAc-conjugated alpha-1 antitrypsin deficiency program, and a longevity and liver health program targeting the AMPKγ1 pathway, with the balance for working capital and general corporate purposes.
Korro Bio, Inc. reported that it hosted a virtual Analyst Day on January 27, 2026. The company made selected presentation slides from this event publicly available by attaching them as an exhibit to this report. These slides are intended to provide additional background and strategic information about Korro Bio’s business for analysts and investors.
Korro Bio, Inc. filed a current report to note that it has updated its corporate presentation. On January 15, 2026, the company prepared new materials for use in meetings with investors, analysts, and other audiences, and filed selected updated slides as an exhibit. These slides, dated January 15, 2026, are incorporated by reference as part of the report, giving stakeholders an officially filed version of the latest overview of the company and its business.
Korro Bio updated the employment agreement for executive Jeffrey Cerio, effective December 15, 2025. His new agreement keeps most prior terms but raises his annual base salary to $425,000. It also increases his cash severance from six to nine months of salary if he is terminated without cause or resigns for good reason, and from nine to 12 months if this occurs within a change in control period.
As part of a broader employee appreciation and retention program, Dr. Cerio will receive a $100,000 cash bonus, paid in two equal installments on December 31, 2025 and on or about June 30, 2026, subject to continued service. He was also granted 41,902 restricted stock units under Korro’s 2023 Stock Option and Incentive Plan, vesting 50% on June 15, 2026 and 50% on December 15, 2026, contingent on continued service through each vesting date.
Korro Bio announced multiple changes. The company and Novo Nordisk agreed to pause their research collaboration and license agreement for 12 months. During this hold period, all research and development obligations are suspended without liability or payment for either party, and Korro will wind down related activities. Novo Nordisk will reimburse certain wind-down costs, while confidentiality, exclusivity, termination terms, and Novo Nordisk’s substitution right remain in effect.
Korro implemented a strategic restructuring, reducing its workforce by approximately 34%. It estimates $2.4 million in one-time restructuring charges, mostly expected in the quarter ending December 31, 2025. Chief Medical Officer Olukemi A. Olugemo, M.D. resigned effective November 12, 2025, and will advise for three months; the post-termination option exercise period for vested options is extended through April 30, 2027. Korro also furnished a press release with financial results for the quarter ended September 30, 2025.
Korro Bio reported that Chief Financial Officer Vineet Agarwal plans to resign effective October 17, 2025 to pursue another opportunity. He has agreed to remain available as an advisor for 30 days to help with the transition. His separation is being handled under his November 2023 employment agreement, with a Separation Agreement providing benefits outside a change in control context, and his vested stock options as of October 17, 2025 may be exercised through March 31, 2027. The company states his departure is not due to any disagreement over management, operations, policies, or practices.
The board has appointed President and Chief Executive Officer Ram Aiyar to serve additionally as interim Chief Financial Officer and principal financial officer starting October 17, 2025. He will not receive additional compensation for these interim duties, and the company notes there are no special arrangements, family relationships, or related-party transactions tied to his appointment. The Separation Agreement with Mr. Agarwal is filed as an exhibit.
Korro Bio, Inc. furnished a press release announcing its financial results for the quarter ended June 30, 2025 as Exhibit 99.1 to a Form 8-K and included a Cover Page Interactive Data file as Exhibit 104. The Form 8-K states the press release is being furnished and expressly notes that the information, including Exhibit 99.1, is not to be deemed "filed" for purposes of Section 18 of the Securities Exchange Act.
The 8-K itself contains no financial figures or tables; readers must review Exhibit 99.1 for the company’s reported results. The report also confirms Korro’s common stock trades under the symbol KRRO on The Nasdaq Capital Market.